Survival analyses based on data from oncology randomised controlled trials (RCTs) provide key evidence for decision- making on treatment options for cancer. In the second of our DRG investigative series, we review the methods and reporting of survival analyses in oncology RCTs and assess the suitability and relevance of survival data reported in RCTs for inclusion into meta-analysis.

What drives the therapy selection test market?

View Now